Lancet Diabetes & Endocrinology

Papers
(The H4-Index of Lancet Diabetes & Endocrinology is 71. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Direct-to-consumer services: improving access to care for people with diabetes and obesity787
Long-term trial outcomes of Roux-en-Y gastric bypass and one anastomosis gastric bypass: tipping the scale676
South Africa to produce insulin for Africa in 2024653
Artificial intelligence and diabetes: time for action and caution546
Type 1 diabetes screening: need for ethical, equity, and health systems perspective502
Anand Hardikar: a scientific nomad searching for the truth483
Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice479
Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality459
Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions431
International Federation for the Surgery of Obesity statement on metabolic bariatric surgery after pharmacotherapy-induced weight loss in clinical obesity420
Reassessing driving safety in diabetes406
Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial360
Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, p305
Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial246
Obesity in people living with type 1 diabetes242
Implications of technology guidelines for low-income and middle-income countries232
Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials204
Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial199
Metastases to the thyroid gland: how does this affect cytohistological diagnoses?191
Better testing and labelling of drugs for people with obesity179
A framework for improving diabetes care in humanitarian emergencies170
World Health Assembly ratifies first global diabetes targets166
Correction to Lancet Diabetes Endocrinol 2022; published online Sept 29. https://doi.org/10.1016/S2213-8587(22)00252-2165
What's preventing us from curbing the obesity crisis?159
Association of glycaemic index and glycaemic load with type 2 diabetes in the PURE study154
Correction to Lancet Diabetes Endocrinol 2022; 10: 489–98154
What does renal failure teach us about our National Health System?152
Correction to Lancet Diabetes Endocrinol 2025; published online April 7. https://doi.org/10.1016/S2213-8587(25)00087-7152
Putting wellbeing at the core of diabetes care146
A roadmap for integrating mental health and diabetes services145
Glycaemic index as part of the diabetes prevention strategy136
The Human Insulin Thermal Solution project—a private sector initiative to address the thermostability of insulin136
Healthy weight for the next generation's health in China133
The urgent need for a diabetes data rights charter132
Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials130
Efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS): a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial130
The promise and hope of GLP-1 receptor agonists124
Retraction and republication—Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses124
Glucose-lowering drugs with cardiovascular benefits as modifiers of critical elements of the human life history120
Lebanon: insulin out of reach after subsidies lifted119
Jennifer Manne-Goehler: at the crossroads of pandemics108
Rising diabetes diagnosis in long COVID107
The role of nurses in diabetes care: challenges and opportunities107
Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis106
Challenging diabetes stigma starts and ends with all of us101
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial – Authors' reply100
Explaining the high rate of progression from prediabetes to type 2 diabetes in China97
The changing character of diabetes complications97
Childhood obesity: a growing pandemic93
Behind the scenes: epigenetic mechanisms rule the roost in pubertal timing91
Levothyroxine treatment in euthyroid women positive for thyroid peroxidase antibodies and recurrent pregnancy loss88
Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study87
The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 202083
CONCEPTT to care: the science of implementation in diabetes care83
The uncomfortable truth about kidney disease in type 1 diabetes83
Understanding the mechanism of prediabetes remission in young people82
Hypothalamic obesity: from basic mechanisms to clinical perspectives81
Aberrant hormone receptors regulate a wide spectrum of endocrine tumors77
Bothersome vasomotor symptoms: a potential early clinical marker of perimenopause?77
A novel diagnostic score for diagnosing arginine vasopressin deficiency (central diabetes insipidus) or primary polydipsia with basal laboratory and clinical parameters: results from two international77
Homing in on the causes of male infertility76
Male hypogonadism: pathogenesis, diagnosis, and management76
Correction to Lancet Diabetes Endocrinol 2022; 10: 407–1775
Women in diabetes research: stepping towards equity75
Diabetes mortality and trends before 25 years of age: an analysis of the Global Burden of Disease Study 201973
Balancing hormonal shifts: exploring the impact of ageing and dietary restriction72
Gender equality: timely and timeless72
Improving HbA1c levels with advanced hybrid closed-loop therapy72
Diabetes: knowing your risk matters72
Correction to Lancet Diabetes Endocrinol 2023; 11: 402–1371
Correction to Lancet Diabetes Endocrinol 2022; 10: 481–8371
0.079468965530396